Cryogenic Control System Migration and Developments towards the UNICOS CERN Standard at INFN

The cryogenic control systems at Laboratori Nazionali di Legnaro (LNL) are undergoing an important and radical modernization, allowing all the plants controls and supervision systems to be renewed in a homogeneous way towards the CERN-UNICOS standard. Before the UNICOS migration project started there were as many as 7 different types of PLC and 7 different types of SCADA, each one requiring its own particular programming language. In these conditions, even a simple modification and/or integration on the program or on the supervision, required the intervention of a system integrator company, specialized in its specific control system. Furthermore it implied that the operators have to be trained to learn the different types of control systems. The CERN-UNICOS invented for LHC [1] has been chosen due to its reliability and planned to run and be maintained for decades on. The complete migration is part of an agreement between CERN and INFN

Continuous vs intermittent Non-Invasive blood pressure MONitoring in preventing postoperative organ failure (niMON): study protocol for an open-label, multicenter randomized trial

Background: Blood pressure has become one of the most important vital signs to monitor in the perioperative setting. Recently, the Italian Society of Anesthesia Analgesia Resuscitation and Intensive Care (SIAARTI) recommended, with low level of evidence, continuous monitoring of blood pressure during the intraoperative period. Continuous monitoring allows for early detection of hypotension, which may potentially lead to a timely treatment. Whether the ability to detect more hypotension events by continuous noninvasive blood pressure (C-NiBP) monitoring can improve patient outcomes is still unclear. Here, we report the rationale, study design, and statistical analysis plan of the niMON trial, which aims to evaluate the effect of intraoperative C-NiBP compared with intermittent (I-NiBP) monitoring on postoperative myocardial and renal injury. Methods: The niMon trial is an investigator-initiated, multicenter, international, open-label, parallel-group, randomized clinical trial. Eligible patients will be randomized in a 1:1 ratio to receive C-NiBP or I-NiBP as an intraoperative monitoring strategy. The proportion of patients who develop myocardial injury in the first postoperative week is the primary outcome; the secondary outcomes are the proportions of patients who develop postoperative AKI, in-hospital mortality rate, and 30 and 90 postoperative days events. A sample size of 1265 patients will provide a power of 80% to detect a 4% absolute reduction in the rate of the primary outcome. Conclusions: The niMON data will provide evidence to guide the choice of the most appropriate intraoperative blood pressure monitoring strategy. Clinical trial registration: Clinical Trial Registration: NCT05496322, registered on the 5th of August 2023